Target type: molecularfunction
Binding to a very-low-density lipoprotein particle, a triglyceride-rich lipoprotein particle that is typically composed of APOB100, APOE and APOCs and has a density of about 1.006 g/ml and a diameter of between 20-80 nm. [GOC:BHF, GOC:mah]
Very-low-density lipoprotein (VLDL) particle binding is a molecular function that involves the specific interaction of proteins with VLDL particles. VLDL particles are a type of lipoprotein that carries triglycerides and cholesterol from the liver to other tissues in the body. The binding of VLDL particles to proteins can have a variety of functions, including:
- **Transport:** VLDL particles are transported through the bloodstream by binding to proteins such as apolipoprotein B-100 (apoB-100), which acts as a ligand for VLDL receptors on target cells. This binding allows for the delivery of triglycerides and cholesterol to tissues that need them.
- **Metabolism:** VLDL particle binding can also regulate lipoprotein metabolism. For example, the binding of VLDL particles to lipoprotein lipase (LPL) on the surface of capillaries allows for the hydrolysis of triglycerides into free fatty acids and glycerol. This process is essential for the delivery of fatty acids to tissues for energy production.
- **Signal transduction:** In some cases, VLDL particle binding can activate signaling pathways that regulate cellular processes. For example, VLDL particles can bind to receptors on the surface of cells, leading to the activation of downstream signaling cascades that can affect gene expression and cell growth.
The specific molecular function of VLDL particle binding is highly dependent on the particular proteins involved. However, in general, VLDL particle binding plays a crucial role in lipid metabolism, transport, and signaling. It is a complex process that involves a variety of interactions between proteins and lipids.'
"
Protein | Definition | Taxonomy |
---|---|---|
Proprotein convertase subtilisin/kexin type 9 | A proprotein convertase subtilisin/kexin type 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NBP7] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
PF-06446846 | PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9. PF-06446846: inhibits translation of PCSK9 ;structure in first source | benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine | antilipemic drug; EC 3.4.21.61 (kexin) inhibitor |